FDA Inspection 1066803 — Bioreliance Ltd.
The FDA completed an inspection of Bioreliance Ltd. on Oct 10, 2017 in Stirling, Scotland. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Oct 10, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Stirling, Scotland (United Kingdom)
Additional details
Mutual Recognition Agreement (MRA)